Since the publication of the addendum of the ICH E9(R1) guideline, estimands have received more attention.
The addendum is definitely a step in the right direction, as it emphasizes the importance of estimating an effect that answers
the clinical question of interest.
However, so far, relatively little attention has been paid to the practical implementability of estimands in clinical trials,
difficulties in doing so and concerns about the developments surrounding estimands.
This seminar will host four experts from academia and the pharmaceutical industry who will give introductions and
perspectives on the theme.
Moreover, the opportunities and potential of recently developed causal inference methods will be discussed
and illustrated using case studies.
Program
14h30-16h15 (CET): Talks given by experts from academia and the pharmaceutical industry
Mouna Akacha, Novartis
Jonathan Bartlett, London School of Hygiene & Tropical Medicine
Kelly Van Lancker, Ghent University
(More details about the content of the talks will follow.)
16h15-16h30 (CET): Floor discussion
Discussant: Stijn Vansteelandt, Ghent University
Target audience
This seminar is aimed at statisticians in the pharmaceutical industry and academia working with clinical trial data.
Registration
This seminar can be followed online or in person at Campus Aula (Ceremoniezaal, Campus Aula, Voldersstraat 9, 9000 Ghent, Belgium).
Participation in the event is free in both cases, but registration via